{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T13:04:03Z","timestamp":1774875843836,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The basophil activation test (BAT) is considered to be the best biomarker to predict autoimmune chronic spontaneous urticaria (aiCSU). To date, few studies have investigated the utility of BAT in real-world clinical practice, the role of aiCSU biomarkers in relation to omalizumab therapy and the degree of association between different aiCSU tests.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To analyse the clinical and laboratory features of a prospective cohort with chronic spontaneous urticaria (CSU) according to their BAT status, as well as to study omalizumab efficacy according to aiCSU biomarkers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective study was conducted from 2010 to 2024 in patients with CSU. BAT alongside other laboratory tests were performed, and clinical and therapeutic features were prospectively collected. Data obtained were compared according to BAT status (positive vs. negative). Furthermore, omalizumab drug survival was typified according to aiCSU biomarkers.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 240 patients were included in the study. Patients who were BAT positive presented more frequently with low IgE levels, higher occurrence of IgG antithyroid peroxidase (anti-TPO) positivity, autologous serum skin test (ASST) positivity, basopenia and eosinopenia. Multivariate logistic regression revealed that ASST [odds ratio (OR) 7.69, 95% confidence interval (CI) 2.81\u201321.0] and anti-TPO (OR 2.63, 95% CI 1.05\u20136.61) were associated with BAT positivity. All aiCSU biomarkers (BAT, ASST, combined ASST\/BAT positivity and low IgE\/anti-TPO+) were associated with significantly shorter omalizumab survival because of treatment failure. In the cohort, both low IgE\/anti-TPO+ and ASST were associated with BAT positivity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The use of BAT in clinical practice delineates a subgroup of patients with specific clinical, laboratory and therapeutic features, including increased omalizumab failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae441","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T19:29:46Z","timestamp":1728934186000},"page":"551-557","source":"Crossref","is-referenced-by-count":3,"title":["Relevance of the basophil activation test in a cohort of 240 patients with chronic spontaneous urticaria"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5821-9780","authenticated-orcid":false,"given":"David","family":"Pesqu\u00e9","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Universitat Aut\u00f2noma de Barcelona (UAB) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn","family":"Andrades","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"Torres-Bos\u00f3","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dulce","family":"Soto","sequence":"additional","affiliation":[{"name":"Department of Immunology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Gimeno","sequence":"additional","affiliation":[{"name":"Department of Immunology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon M","family":"Pujol","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Y\u00e9lamos","sequence":"additional","affiliation":[{"name":"Department of Immunology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-7753","authenticated-orcid":false,"given":"Ana M","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital del Mar Research Institute , Barcelona ,","place":["Spain"]},{"name":"Universitat Pompeu Fabra (UPF) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2025022416224995100_llae441-B1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1111\/all.13949","article-title":"Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: results of the PURIST Study","volume":"74","author":"Schoepke","year":"2019","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2025022416224995100_llae441-B3","doi-asserted-by":"crossref","first-page":"742470","DOI":"10.3389\/fimmu.2021.742470","article-title":"What basophil testing tells us about CSU patients\u00a0\u2013\u200c\u00a0results of the CORSA Study","volume":"12","author":"Marcelino","year":"2021","journal-title":"Front Immunol"},{"key":"2025022416224995100_llae441-B4","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.jaip.2021.07.043","article-title":"Autoimmune chronic spontaneous urticaria detection with IgG Anti-TPO and total IgE","volume":"9","author":"Kolkhir","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B5","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jaip.2023.05.039","article-title":"Positive basophil tests are linked to high disease activity and other features of autoimmune chronic spontaneous urticaria: a systematic review","volume":"11","author":"Mo\u00f1ino-Romero","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/jdv.17131","article-title":"Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions","volume":"35","author":"Baumann","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025022416224995100_llae441-B7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaip.2015.11.025","article-title":"Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria","volume":"4","author":"Palacios","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B8","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaci.2016.07.047","article-title":"Serum autoreactivity \u00adpredicts time to response to omalizumab therapy in chronic spontaneous urticaria","volume":"139","author":"Gericke","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2025022416224995100_llae441-B9","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.5415\/apallergy.2020.10.e12","article-title":"Relationship between changes in the 7-day urticaria activity score after treatment with omalizumab and the responsiveness of basophils to Fc\u03b5RI stimulation in patients with chronic spontaneous urticaria","volume":"10","author":"Endo","year":"2020","journal-title":"Asia Pac Allergy"},{"key":"2025022416224995100_llae441-B10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/all.12056","article-title":"EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria","volume":"68","author":"Konstantinou","year":"2013","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA\u00b2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B12","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA\u00b2LEN\/EDF\/WAO guideline for the definition, classification, diagnosis and management of urticaria","volume":"73","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B13","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1016\/j.jaip.2023.09.002","article-title":"Autoimmune diseases and low baseline IgE in chronic spontaneous urticaria: a clinical and therapeutic prospective analysis in real-life clinical practice","volume":"11","author":"Pesqu\u00e9","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.4168\/aair.2021.13.4.545","article-title":"Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria","volume":"13","author":"Kolkhir","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"2025022416224995100_llae441-B15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.ad.2018.07.005","article-title":"Algorithm for treatment of chronic spontaneous urticaria with omalizumab","volume":"109","author":"Spertino","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"2025022416224995100_llae441-B16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.18176\/jiaci.0323","article-title":"Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria","volume":"29","author":"Gim\u00e9nez-Arnau","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025022416224995100_llae441-B17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ad.2020.01.012","article-title":"Ciclosporin: an old ally in the treatment of chronic spontaneous urticaria","volume":"112","author":"Pinilla Mart\u00edn","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"2025022416224995100_llae441-B18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/iid3.125","article-title":"Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease","volume":"4","author":"Curto-Barredo","year":"2016","journal-title":"Immun Inflamm Dis"},{"key":"2025022416224995100_llae441-B19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2340\/00015555-2654","article-title":"Basophil Fc\u03b5RI expression in chronic spontaneous urticaria: a potential immunological predictor of response to omalizumab therapy","volume":"97","author":"Deza","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2025022416224995100_llae441-B20","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.25576","article-title":"Solar urticaria: an ambispective study in a long-term follow-up cohort with emphasis on therapeutic predictors and outcomes","volume":"104","author":"Pesqu\u00e9","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"2025022416224995100_llae441-B21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000451084","article-title":"Positive CD63 basophil activation tests are common in children with chronic spontaneous urticaria and linked to high disease activity","volume":"171","author":"Netchiporouk","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"2025022416224995100_llae441-B22","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/all.12578","article-title":"Interval shifts in basophil measures correlate with disease activity in chronic spontaneous urticaria","volume":"70","author":"Oliver","year":"2015","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B23","doi-asserted-by":"crossref","first-page":"657211","DOI":"10.3389\/fimmu.2021.657211","article-title":"Lower IgA levels in chronic spontaneous urticaria are associated with lower IgE Levels and autoimmunity","volume":"12","author":"Sauer","year":"2021","journal-title":"Front Immunol"},{"key":"2025022416224995100_llae441-B24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1684\/ejd.2019.3680","article-title":"The CD63 basophil activation test as a diagnostic tool for assessing autoimmunity in patients with chronic spontaneous urticaria","volume":"29","author":"Hossein Zadeh Attar","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2025022416224995100_llae441-B25","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1111\/all.13215","article-title":"Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria","volume":"72","author":"Rauber","year":"2017","journal-title":"Allergy"},{"key":"2025022416224995100_llae441-B26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaip.2019.08.025","article-title":"Eosinopenia, in chronic spontaneous urticaria, is associated with high disease activity, autoimmunity, and poor response to treatment","volume":"8","author":"Kolkhir","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B27","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/jdv.13912","article-title":"Basophil CD63 expression in chronic spontaneous urticaria: correlation with allergic sensitization, serum autoreactivity and basophil reactivity","volume":"31","author":"Chen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025022416224995100_llae441-B28","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jaip.2017.10.030","article-title":"Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria","volume":"6","author":"Straesser","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025022416224995100_llae441-B29","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.aller.2011.09.009","article-title":"Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test","volume":"40","author":"Rodr\u00edguez-Trabado","year":"2012","journal-title":"Allergol Immunopathol (Madr)"},{"key":"2025022416224995100_llae441-B30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2045-7022-2-19","article-title":"A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria","volume":"2","author":"Iqbal","year":"2012","journal-title":"Clin Transl Allergy"},{"key":"2025022416224995100_llae441-B31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1081-1206(10)60266-9","article-title":"A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria","volume":"103","author":"Najib","year":"2009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2025022416224995100_llae441-B32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4168\/aair.2021.13.2.206","article-title":"Total IgE as a marker for chronic spontaneous urticaria","volume":"13","author":"Altrichter","year":"2021","journal-title":"Allergy Asthma Immunol Res"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae441\/60885065\/llae441.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/551\/60885065\/llae441.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/3\/551\/60885065\/llae441.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T16:23:07Z","timestamp":1740414187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/3\/551\/7823574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,10,16]]},"published-print":{"date-parts":[[2025,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae441","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,16]]}}}